Synthesis and structure-activity relationships of pirfenidone derivatives as anti-fibrosis agents <i>in vitro</i>.
Shi X, Yu Z, Zhu C, Jiang L, Geng N, Fan X, Guan Z, Lu X.
Pirfenidone (PFD) was the first approved drug by FDA for the treatment of idiopathic pulmonary fibrosis (IPF). However, the rapid metabolism of 5-methyl of PFD increases the risk of side effects in clinics. Thus, in this paper, a common practice that a stable amide bond linking various groups used to replace 5-methyl of PFD in medicinal chemistry was applied, and total 18 PFD derivatives were synthesized. All compounds were investigated for their antiproliferation activities against NIH3T3 cells and the structure-activity relationships of the target compounds were also discussed. Among them, <b>YZQ17</b> possessed potent antiproliferation activity compared to PFD and better potency in inhibiting TGF-β-induced migration of NIH3T3 cells at a much lower concentration than that of PFD. In addition, <b>YZQ17</b> dramatically inhibited the expression levels of fibrotic markers α-SMA, collagen I, and fibronectin. Moreover, further mechanistic studies confirmed that <b>YZQ17</b> exhibited this considerable anti-fibrosis activity <i>via</i> the TGF-β/Smad2/3 dependent pathway. Finally, the results of human and rat liver microsomes assay <i>in vitro</i> and pharmacokinetic assay in rats confirmed that <b>YZQ17</b> showed better pharmacokinetics than that of PFD. Collectively, the preliminary study of PFD derivatives modified by the amide group indicated that <b>YZQ17</b> could be regarded as a lead compound for further investigation and optimization.